

## 2019 年実績

1. Nakano T, Okano H, Takahashi M, Nagashima S, Shiraki K, Oya Y, Inoue H, Ohmori S, Tsukimoto M, Ishida S, Fujimoto S, Kobayashi M, Yamawaki M, Kumagai M, Ninomiya J, Maegawa T, Kojima Y, Araki J, Hamaoka S, Horiike S, Yoshimura H, Takeuchi K, Itoh K, Akachi S, Uraki S, Yamamoto N, Ogura S, Sugimoto K, Yoshikawa K, Hasegawa H, Iwasa M, Takei Y, Okamoto H.  
**Changing clinical and molecular characteristics of hepatitis E virus infection in Mie Prefecture, Japan: Disappearance of indigenous subtype 3e strains.**  
*Hepatol Res.* 2019 Sep;49(9):1003–1014. doi: 10.1111/hepr.13357. Epub 2019 Jun 7. PMID: 31026368.
2. Wada H, Matsumoto T, Yamashita Y, Ohishi K, Ikejiri M, Katayama N.  
**Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotypic monoclonal antibodies: comment.**  
*J Thromb Haemost.* 2019; 7(3):555–556
3. Matsumoto T, Wada H, Ohishi K, Yamashita Y, Ikejiri M, Katayama N.  
**Comments to: An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia by APTT Waveform, Peak Heights of APTT Waveform Are Useful for Diagnosing Hemophilia or Inhibitor.**  
*Clin Appl Thromb Hemost.* 2019 Jan–Dec
4. Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S.  
**Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation, Wada H.: Sepsis-associated disseminated intravascular coagulation and its differential diagnoses.**  
*J Intensive Care.* 2019 May 20;7:32
5. Iba T, Levy JH, Thachil J, Wada H, Levi M.  
**Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis; The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases.**  
*Thromb Res.* 2019; 179: 11–14
6. Suzuki K, Matsumoto T, Iwashita Y, Ishikura K, Fujioka M, Wada H, Katayama N, Imai H.  
**Clinicopathological features of TAFRO syndrome complicated by acquired hemophilia A and development of cardiopulmonary arrest that were successfully treated with VA-ECMO and tocilizumab.**  
*Int J Hematol.* 2019; 109 (6): 737–743
7. Habe K, Wada H, Higashiyama A, Akeda T, Tsuda K, Mori R, Kakeda M, Yamanaka K, Mizutani H.  
**Elevated plasma D-dimer levels in dermatomyositis patients with cutaneous manifestations.**  
*Sci Rep.* 2019; 9(1): 1410
8. Iba T, Arakawa M, Mochizuki K, Nishida O, Wada H, Levy JH.  
**Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation.**  
*Clin Appl Thromb Hemost.* 2019 Jan–Dec
9. Yamashita Y, Suzuki K, Matsumoto T, Ikejiri M, Ohishi K, Katayama N, Suzuki-Inoue K, Wada H.  
**Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy.**  
*Thromb Res.* 2019; 178: 54–58
10. Suzuki K, Wada H, Matsumoto T, Ikejiri M, Ohishi K, Yamashita Y, Imai H, Iba T, Katayama N.  
**Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.**  
*Thromb J* 2019; 17:12
11. Kageyama Y, Matsumoto T, Tawara I, Wada H, Katayama N.  
**Life-Threatening Tongue and Retropharyngeal Hemorrhage in a Patient with Hemophilia A with Inhibitors.**  
*Am J Case Rep.* 2019;20: 1022–1026.
12. Suzuki Y, Shiba M, Wada H, Yasuda R, Toma N, Suzuki H.  
**Case of Hemorrhagic Moyamoya Disease Associated with Von Willebrand Disease.**  
*World Neurosurg.* 2019; 130: 335–338